World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

Schizophrenia Research

Volumn 100, Issue 1-3, 2008, Pages 20-38

  Tandon, Rajiv ^a   Belmaker, R H ^c   Gattaz, Wagner F ^d   Lopez Ibor Jr , Juan J ^e   Okasha, Ahmed ^f   Singh, Bruce ^g   Stein, Dan J ^h   Olie, Jean Pierre ⁱ   Fleischhacker, W Wolfang ^j   Moeller, Hans Juergen ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f AIN SHAMS UNIVERSITY   (Egypt)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ CENTRE HOSPITALIER SAINTE ANNE   (France)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENAZINE; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; BUTAPERAZINE; CLOPENTHIXOL; CLOZAPINE; CYAMEMAZINE; EMONAPRIDE; FLUPENTIXOL; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PIPAMPERONE; PIPERACETAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; THIOPROPERAZINE; TIAPRIDE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ARTICLE; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GOVERNMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; METABOLIC DISORDER; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHIATRY; QUALITY OF LIFE; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DRUG INDUSTRY; FINANCING, GOVERNMENT; HUMANS; INFORMATION DISSEMINATION; INTERNATIONAL COOPERATION; META-ANALYSIS AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 39949085594     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.11.033     Document Type: Article

References (139)

1. Addington D.E., Pantelis C., Dineen M., et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: An 8-week, double-blind, multicenter trial. J. Clin. Psychiatry 65 (2004) 1624-1633
2. Allison E., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 (1999) 1686-1696
3. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 161 Supplement 2 (2004) 1-56
4. Anthony W.A. Recovery from mental illness: the guiding vision of the mental health service system in the 1990's. Psychosoc. Rehabil. J. 16 (1993) 11-23
5. Azorin J.M., Strub N., and Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int. Clin. Psychopharmacol. 21 (2006) 49-56
6. Breier A., Berg P.H., Thakore J.H., et al. Olanzapine versus ziprasidone: results of a 28-week, double-blind study in patients with schizophrenia. Am. J. Psychiatry 162 (2005) 1879-1887
7. Carpenter W.T., and Gold J.M. Another view of therapy for cognition in schizophrenia. Biol. Psychiatry 51 (2002) 972-978
8. Casey D.E. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr. 11 Suppl 7 (2006) 25-31
9. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158 (2001) 518-526
10. Chrzanowski W.K., Marcus R.N., Torbeyns A., et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine. Psychopharmacology 189 (2006) 259-266
11. Committee on Crossing the Quality Chasm. Adaptation to Mental and Addictive Disorders, Institute of Medicine of the National Academy of Sciences. Improving the quality of health care for mental health and substance-use conditions (2005), The National Academies Press, Washington, D.C. http://www.nap.edu www.nap.edu
12. Conley R.R., and Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry 158 (2001) 765-774
13. Constantine R.J., Richard S.M., Surles R.C., et al. Optimizing pharmacotherapy of schizophrenia: tools for the psychiatrist. Curr. Psychosis Ther. Rep. 4 (2006) 5-11
14. Correll C.U., Leucht S., and Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry 161 (2004) 414-425
15. Davidson M., Emsley R., Kramer M., et al. Efficacy, safety, and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. 93 (2007) 117-130
16. Davies L.M., Lewis S., Jones P.B., et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. Br. J. Psychiatry 191 (2007) 14-22
17. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 (2003) 553-564
18. Davis J.M., Marder S.R., and Tamminga C.A. Switch or stay. Am. J. Psychiatry 163 (2006) 2032-2033
19. Dundar Y., Dodd S., Dickson R., et al. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technol. Assess. 10 5 (2006) 1-145
20. ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publication # ADM 76-388). In: Guy W. (Ed). Rockville, MD, US Department of Health, Education, and Welfare (1976)
21. Edlinger M., Baumgartner S., Eltanaihi-Furtmuller N., et al. Switching between second-generation antipsychotics: Why and how?. CNS Drugs 19 (2005) 27-42
22. Erhart S.M., Marder S.R., and Carpenter W.T. Treatment of negative symptoms: Future prospects. Schizophr. Bull. 32 (2006) 234-237
23. Essock S.M., Covell N.H., Davis S.M., et al. Effectiveness of switching antipsychotic medications. Am. J. Psychiatry 163 (2006) 2090-2095
24. Falkai P., Wobrock T., Lieberman J., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. World J. Biol. Psychiatry 6 (2005) 132-191
25. Fleischhacker W.W., Keet I.P., and Kahn R.S. The European First-Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophr. Res. 78 (2005) 147-156
26. Franciosi L.P., Kasper S., Garber A.J., et al. Advancing the treatment of people with mental illness: A call to action in the management of metabolic issues. J. Clin. Psychiatry 66 (2005) 790-798
27. Freedman R., Carpenter W.T., Davis J.M., et al. The costs of drugs for schizophrenia. Am. J. Psychiatry 163 (2006) 2029-2031
28. Geddes J., Freemantle N., Harrison P., et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 231 (2000) 1371-1376
29. Gilbody S., Wahlbeck K., and Adams C. Randomized, controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr. Scand. 105 (2002) 243-251
30. Glenny A.M., Altman D.G., Song F., et al. Indirect comparisons of competing interventions. Health Technol. Assess. 9 26 (2005) 1-148
31. Hansen K., Lancon C., and Toumi M. Pharmacoeconomic modeling in schizophrenia: trap or support for decision makers?. Eur. J. Health Econ. 7 (2006) 19-29
32. Harvey P.D., and Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158 (2001) 176-184
33. Heres S., Davis J., Maino K., et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry 163 (2006) 185-194
34. Hoenberg K., and Goetz K. Antipsychotics: Analysis of Disease Markets and Emerging Agents (2006), Decision Resources, Inc., Waltham, Massachusetts
35. Honer W.G., Thornton A.E., Sherwood M., et al. Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 21 (2007) 699-714
36. Hugenholtz G.W., Heerdink E.R., Stolker J.J., et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J. Clin. Psychiatry 67 (2006) 897-903
37. Janicak P.G. The CATIE study and its implications for antipsychotic drug use. Essent. Psychopharmacol. 7 (2006) 53-63
38. Jeste D.V., Barak Y., Madhusoodanan S., et al. International multi-site double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am. J. Geriatr. Psychiatry 11 (2003) 638-647
39. Jones P.B., Davies L., Barnes T.R., et al. Randomized controlled trial of effect on quality of life of second-generation versus first generation antipsychotic drugs in schizophrenia. Arch. Gen. Psychiatry 63 (2006) 1079-1087
40. Kane J.M. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J. Clin. Psychiatry 67 Supplement 5 (2006) 9-14
41. Kane J.M. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). J. Clin. Psychiatry 67 (2006) 831-832
42. Kane J.M. Tardive dyskinesia Circa 2006. Am. J. Psychiatry 163 (2006) 1316-1318
43. Kane J.M., Honigfeld G., Singer J., and Meltzer H.Y. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45 (1988) 789-796
44. Kane J.M., Leucht S., Carpenter D., et al. Expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psychiatry 64 Suppl 12 (2003) 1-100
45. Kane R.L., Wang J., and Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. J. Clin. Epidemiol. 60 (2007) 241-249
46. Kapur S., and Remington G. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52 (2001) 503-517
47. Kasper S., and Winkler D. Addressing the limitations of the CATIE study. World J. Biol. Psychiatry 7 (2006) 126-127
48. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
49. Keefe R.S., Bilder R.M., Harvey P.D., et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31 (2006) 2033-2046
50. Keefe R.S.E., Bilder R.M., Davis S.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 64 (2007) 633-647
51. Kinon B.J., Noordsy D.L., Liu-Siefert H., et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 26 (2006) 453-461
52. Kinon B.J., Lipkovich I., Edwards S.B., et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J. Clin. Psychopharmacol. 26 (2006) 157-162
53. Lecrubier Y., Quintin P., Bouhassira M., et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled trial. Acta Psychiatr. Scand. 114 (2006) 319-327
54. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35 (1999) 51-68
55. Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
56. Leucht S., Kane J.M., Kissling W., et al. What does the PANSS mean?. Schizophr. Res. 79 (2005) 231-238
57. Lewis S.W., Davies L., Jones P.B., et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol. Assess. 10 17 (2006) 1-182
58. Lewis S.W., Barnes T.R., Davies L., et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 32 (2006) 715-723
59. Lexchin J., Bero L.A., Djulbegovic B., and Clark O. Pharmaceutical industry sponsorship and research outcome and quality. BMJ 326 (2003) 1167-1170
60. Lieberman J.A., Phillips M., Gu H., et al. Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: A 52-week randomized trial of clozapine versus chlorpromazine. Neuropsychopharmacology 28 (2003) 995-1003
61. Lieberman J.A., Stroup S.T., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
62. Marder S.R., Essock S.M., Miller A.M., et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 161 (2004) 1334-1349
63. Martin S., Ljo H., Peuskens J., and Thirumalai S. A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia. Short-term results at two months. Curr. Med. Res. Opin. 18 (2002) 355-362
64. Martin J.L.R., Perez V., Sacristan M., and Alvarez E. Is grey literature essential for a better control of publication bias in psychiatry?. Eur. Psychiatry 20 (2005) 550-553
65. McAlister F.A., Laupacis A., Wells G.A., and Sackett D.L. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 282 (1999) 1371-1377
66. McCue R.E., Waheed R., Urcuyo L., et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br. J. Psychiatry 189 (2006) 433-440
67. McEvoy J.P., Lieberman J.A., Stroup T.S., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment. Am. J. Psychiatry 163 (2006) 600-610
68. McEvoy J.P., Lieberman J.A., Perkins D.O., et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am. J. Psychiatry 164 (2007) 1050-1060
69. McQuade R.D., Stock E., Marcus R., et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65 suppl.18 (2004) 47-56
70. Melander H., Ahlqvist-Rastad D.J.M., Meijer G., and Beerman B. Evidence b(i)ased medicine- selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326 (2003) 1171-1173
71. Meltzer H.Y. What's atypical about atypical antipsychotic drugs?. Curr. Opin. Pharmacol. 4 (2004) 53-57
72. Meltzer H.Y., and Bobo W.V. Interpreting the efficacy findings in the CATIE study: what the clinician should know. CNS Spectr. 11 Suppl 7 (2006) 14-24
73. Meltzer H.Y., Alphs L., Green A.I., et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60 (2003) 82-91
74. Miller A.L., Hall C.S., Buchanan R.W., et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J. Clin. Psychiatry 65 (2004) 500-508
75. Mismetti P., Cucherat M., and Laporte S. Meta-analyses or mega-trials: same level of proof?. Presse. Med. 36 (2007) 524-530
76. Moller H.-J. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J. Biol. Psychiatry 1 (2000) 75-91
77. Moller H.-J. Management of the negative symptoms of schizophrenia. New treatment options. CNS Drugs 17 (2003) 793-823
78. Moller H.-J. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur. Arch. Psychiatry Clin. Neurosci. 255 (2005) 371-372
79. Moller H.-J. Do effectiveness studies tell us the real truth?. World J. Biol. Psychiatry 8 (2007) 138-140
80. Montgomery J.H., Byerly M., Carmody T., et al. An analysis of the effect of funding source in randomized clinical trials of second-generation antipsychotics for the treatment of schizophrenia. Control. Clin. Trials 25 (2004) 598-612
81. Mortimer A., Martin S., Loo H., et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int. Clin. Psychopharmacol. 19 (2004) 63-69
82. Motlova L., Spaniel F., Hoschl C., and Balon R. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?. Ann. Clin. Psychiatry 19 (2007) 133-143
83. Mullen J., Jibson M.D., and Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin. Ther. 23 (2001) 1839-1854
84. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand. 115 (2007) 260-267
85. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
86. Noble Jr. J.H. Meta-analysis: Methods, strengths, weaknesses, and political uses. J. Clin. Lab. Med. 147 (2006) 7-20
87. Olie J.P., Spina E., Murray S., and Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int. Clin. Psychopharmacol. 21 (2006) 143-151
88. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 799-812
89. Patel V., Arya R., Chatterjee S., et al. Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet 370 (2007) 991-1005
90. Perlis R.H., Perlis C.S., Wu Y., et al. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am. J. Psychiatry 162 (2005) 1957-1960
91. Peuskens J., Bech P., Moller H.-J., et al. Amisulpiride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res. 88 (1999) 107-117
92. Pocock S.J., and Elbourne D.R. Randomized trials or observational tribulations?. N. Engl. J. Med. 342 (2000) 1907-1909
93. Polsky D., Doshi J.A., Bauer M.S., and Glick H.A. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am. J. Psychiatry 163 (2006) 2047-2056
94. Potkin S.G., Saha A.R., Kujawa M.J., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 (2003) 681-690
95. Potkin S.G., Gharabawi G.M., Greenspan A.J., et al. A double-blind comparison of risperidone, quetiapine, and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr. Res. 85 (2006) 254-265
96. Rosenheck R.A., Leslie D.L., Sindelar J., et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry 163 (2006) 2080-2089
97. Rosenheck R., Swartz M., McEvoy J., et al. Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. Expert Rev. PharmacoEcon. Outcomes Res. 7 (2007) 103-111
98. Rosenheck R., Stroup S.T., Keefe R.S.E., et al. Study samples key to assessing risk. The authors reply. Curr. Psychiatry 6 1 (2007) 3-19. http://www.currentpsychiatry.com www.currentpsychiatry.com
99. Rothwell P.M. External validity of randomized controlled trials: 'to whom do the results of this trial apply?'. Lancet 365 (2005) 82-93
100. Safer D.J. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J. Nerv. Ment. Dis. 190 (2002) 583-592
101. Scherer R.W., Langenberg P., and von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst. Rev. MR000005 (2007)
102. Schomerus G., Borsche J., Matschinger H., and Angermeyer M.C. Public knowledge about causes and treatment for schizophrenia: a representative population study. J. Nerv. Ment. Dis. 194 (2006) 622-624
103. Schooler N.R. The efficacy and safety of conventional and atypical antipsychotics in first-episode schizophrenia: A review of the literature. Clin. Schizophr. Relat. Psychosis 1 (2007) 27-42
104. Seale C., Chaplin R., Lelliott P., and Quirk A. Sharing decisions in consultations involving anti-psychotic medication: a qualitative study of psychiatrists' experiences. Soc. Sci. Med. 62 (2006) 2861-2873
105. Sechter D., Peuskens J., Fleurot O., et al. Amisulpride vs risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 27 (2002) 1071-1081
106. Simpson G.M., Glick I.D., Weiden P.J., et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia and schizoaffective disorder. Am. J. Psychiatry 161 (2004) 1837-1847
107. Song F., Altman D.G., Glenny A.M., and Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 326 (2003) 472-475
108. Stroup T.S., McEvoy J.P., Swartz M.S., et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Antipsychotic Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 29 (2003) 15-31
109. Stroup T.S., Lieberman J.A., McEvoy J.P., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163 (2006) 611-622
110. Stroup S.T., Alves W.M., Hamer R.M., and Lieberman J.A. Clinical trials for antipsychotic drugs: design conventions, dilemmas, and innovations. Nat. Rev.-Drug. Discov. 5 (2006) 133-146
111. Swartz M.S., Perkins D.O., Stroup S.T., et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 164 (2007) 428-436
112. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: What does CATIE tell us? - part 1. Int. Drug Ther. Newsl. 41 (2006) 51-58
113. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what does CATIE tell us? - part 2. Int. Drug Ther. Newsl. 41 (2006) 67-74
114. Tandon R. Antipsychotic treatment of schizophrenia: two steps forward, one step back. Curr. Psychiatry Rep. 9 (2007) 263-264
115. Tandon R., and Jibson M.D. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann. Clin. Psychiatry 14 (2002) 123-129
116. Tandon R., and Fleischhacker W.W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophr. Res. 79 (2005) 145-155
117. Tandon R., and Jibson M.D. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int. J. Psychiatry Clin. Pract. 9 (2005) 204-212
118. Tandon R., and Nasrallah H.A. Subjecting meta-analyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics. The authors reply. Arch. Gen. Psychiatry 63 (2006) 935-939
119. Tandon R., and Constantine R.J. Avoiding EPS is the key to realizing "atypical" benefits. Curr. Psychiatry 5 11 (2006) 35-45. http://www.currentpsychiatry.com www.currentpsychiatry.com
120. Tandon R., Marcus R.N., Stock E.G., et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia and schizoaffective disorder in general psychiatric practice. Schizophr. Res. 84 (2006) 77-89
121. Tandon R., Carpenter W.T., and Davis J.M. First- and second- generation antipsychotics: Learning from CUtLASS and CATIE. Arch. Gen. Psychiatry 64 (2007) 977-978
122. Tandon R., Targum S.D., Nasrallah H.A., and Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J. Psychiatr. Pract. 12 (2006) 348-363
123. Tarsy D., and Baldessarini R.J. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?. Mov. Disord. 21 (2006) 589-598
124. Tenback D.E., van Harten P.N., Slooff C.J., et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am. J. Psychiatry 163 (2006) 1438-1440
125. Texier G., Meynard J.B., Michel R., et al. Submitting studies without significant results. Presse. Med. 36 (2007) 541-550
126. Tharyan P. The Cochrane Schizophrenia Group: Preparing, maintaining and disseminating the evidence for interventions used for people with schizophrenia. Int. Rev. Psychiatry 17 (2005) 115-121
127. Tiihonen J., Wahlbeck K., Lonnqvist J., et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 33 (2006) 224-230
128. Tollefson G.D., Sanger T.M., Lu Y., and Thieme M.E. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Am. J. Psychiatry 55 (1998) 250-258
129. Tran P.V., Hamilton S.H., Kuntz A.J., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 (1997) 407-418
130. Tunner T.P., and Salzer M.S. Consumer perspectives on quality of care in the treatment of schizophrenia. Adm. Policy Ment. Health. 33 (2006) 674-681
131. Tuunainen A., Wahlbeck K., and Gilbody S.M. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr. Res. 56 (2002) 1-10
132. Volavka J., Czobor P., Sheitman B., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 159 (2002) 255-262
133. Weiden P.J. EPS profiles: The atypical antipsychotics are not all the same. J. Psychiatr. Pract. 13 (2007) 13-24
134. Weiden P.J., Simpson G.M., Potkin S.G., et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J. Clin. Psychiatry 64 (2003) 58-588
135. Williamson P.R., Gamble C., Altman D.G., and Hutton J.L. Outcome selection bias in meta-analysis. Stat. Methods Med. Res. 14 (2005) 515-524
136. World Psychiatric Associations. The usefulness and use of second-generation antipsychotic medications. General assembly resolution, August 26, Yokohama (2002). http://www.peoplewho.org/WPA2ndgenanti-pDOC.doc www.peoplewho.org/WPA2ndgenanti-pDOC.doc
137. Zarin D.A., Tse T., and Ide N.C. Trial registration at ClinicalTrials.gov between May and October 2005. N. Engl. J. Med. 353 (2005) 2779-2787
138. Zhong K.X., Sweitzer D.E., Hamer R.M., and Lieberman J.A. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J. Clin. Psychiatry 67 (2006) 1093-1103
139. Zimbroff D.L., Kane J.M., Tamminga C.A., et al. Controlled dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry 154 (1997) 782-791